FDA Adverse Event Injury Summary report: N

ZEPHYR ENDOBRONCHIAL VALVE (EBV)

MDR report key: 11631703 · Received April 7, 2021

Report

Report Number
3007797756-2021-00054
Event Type
Injury
Date Received
April 7, 2021
Date of Event
March 1, 2021
Report Date
April 7, 2021
Product Code
NJK
UDI-DI
00811907030423
PMA / PMN Number
P180002
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
003

Narratives

Additional Manufacturer Narrative · 1

PLEURAL EFFUSION IS A KNOWN, ANTICIPATED SIDE EFFECT ASSOCIATED WITH THE ZEPHYR VALVE TREATMENT (CRINER ET AL. A MULTICENTER RANDOMIZED CONTROLLED TRIAL OF ZEPHYR ENDOBRONCHIAL VALVE TREATMENT IN HETEROGENEOUS EMPHYSEMA (LIBERATE). AM J RESPIR CRIT CARE MED. 2018; 198 (9): 1151-1164). IN THE LIBERATE STUDY (IDE CLINICAL STUDY USED TO SUPPORT PMA P180002'S APPROVAL), 7.0% OF THE ZEPHYR VALVE SUBJECTS AND 0% OF THE CONTROL SUBJECTS EXPERIENCED PLEURAL EFFUSION DURING THE TREATMENT PERIOD (LESS THAN OR EQUAL TO 45 DAYS). THE ZEPHYR EBV SYSTEM IFU SPECIFICALLY REFERENCES PLEURAL EFFUSION AS A KNOWN SIDE EFFECT OF THIS PROCEDURE. THE REPORTED EVENT ALIGNS WITH THE EXPERIENCE OBSERVED IN THE LIBERATE CLINICAL STUDY AND IS AN EXPECTED SIDE EFFECT OF THE ZEPHYR VALVE TREATMENT. THE REPORTED EVENT WAS FORESEEABLE AND CLINICALLY ACCEPTABLE IN VIEW OF THE EXPECTED PATIENT BENEFIT FROM THE TREATMENT.

Description of Event or Problem · 1

ON (B)(6) 2021, THE PATIENT UNDERWENT A BRONCHOSCOPIC LUNG VOLUME REDUCTION PROCEDURE WITH THREE ZEPHYR VALVES IMPLANTED IN THE RIGHT UPPER LOBE. THE POST-PROCEDURE X-RAY SHOWED A LOCULATED EFFUSION. THE PATIENT HAD ANOTHER BRONCHOSCOPY PROCEDURE TO CLEAR SECRETIONS ON (B)(6) 2021. ON (B)(6) 2021, THE PATIENT HAD A CT SCAN TO ADDRESS THE EFFUSION AND 2 CHEST DRAINS WERE PLACED. AFTER RESOLUTION, BOTH CHEST DRAINS WERE REMOVED ON (B)(6) 2021 AND PATIENT WAS DISCHARGED ON (B)(6) 2021.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
524825 ZEPHYR ENDOBRONCHIAL VALVE (EBV) ENDOBRONCHIAL VALVE NJK ZEPHYR 5.5-LP EBV 504831-V7.0 00811907030423

Patients

Seq Age Sex Outcome Treatment
1 Hospitalization| R